Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: Results of a prospective longitudinal 5-year follow-up study

Vox Sanguinis

Volumn 104, Issue 1, 2013, Pages 46-54

  Mueller, M M ^a   Bialleck, H ^a   Bomke, B ^a,c   Brauninger, S ^a   Varga, C ^a   Seidl, C ^a   Seifried, E ^a   Tonn, T ^a,d   Bonig, H ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Allogeneic; Long term follow up; Longitudinal study; Stem cell donor safety; Volunteer stem cell donor

Indexed keywords

CD34 ANTIGEN; PARACETAMOL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALOPECIA; APHERESIS; ARTHRALGIA; ARTICLE; BIOCHEMISTRY; BLOOD EXAMINATION; BONE PAIN; CD4 CD8 RATIO; DIZZINESS; DONOR; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEART PALPITATION; HEMATOMA; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MALAISE; MALE; MUSCLE CRAMP; MYALGIA; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; SPLEEN SIZE; SPLENOMEGALY; STEM CELL MOBILIZATION; T LYMPHOCYTE; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS;

ADULT; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; BLOOD SAFETY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MALE; PHENOTYPE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; STEM CELLS; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871314905     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2012.01632.x     Document Type: Article

References (46)

1. Appelbaum FR: Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357:1472-1475.
2. Ballen KK, King RJ, Chitphakdithai P, et al.: The national marrow donor program 20years of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 9(Suppl):2-7.
3. de la Rubia J, de Arriba F, Arbona C, et al.: Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008; 93:735-740.
4. Foeken LM, Green A, Hurley CK, et al.: Monitoring the international use of unrelated donors for transplantation: the WMDA annual reports. Bone Marrow Transplant 2010; 45:811-818.
5. Heldal D, Brinch L, Tjonnfjord G, et al.: Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints. Bone Marrow Transplant 2002; 29:479-486.
6. Martino M, Console G, Dattola A, et al.: Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009; 44:163-168.
7. Pamphilon D, Mackinnon S, Nacheva E, et al.: The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant 2006; 38:699-700.
8. Pulsipher MA, Chitphakdithai P, Miller JP, et al.: Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113:3604-3611.
9. Rowley SD, Donaldson G, Lilleby K, et al.: Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97:2541-2548.
10. Siddiq S, Pamphilon D, Brunskill S, et al.: Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 2009; 21:CD006406.
11. Tassi C, Tazzari PL, Bonifazi F, et al.: Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005; 36:289-294.
12. Anderlini P, Przepiorka D, Champlin R, et al.: Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood 1996; 88:2819-2825.
13. Anderlini P, Przepiorka D, Seong D, et al.: Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996; 36:590-595.
14. Froberg MK, Garg UC, Stroncek DF, et al.: Changes in serum osteocalcin and bone-specific alkaline phosphatase are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Transfusion 1999; 39:410-414.
15. Miller JP, Perry EH, Price TH, et al.: Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant 2008; 9(Suppl):29-36.
16. Kaplinsky C, Trakhtenbrot L, Hardan I, et al.: Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF. Bone Marrow Transplant 2003; 32:31-34.
17. Bennett CL, Evens AM, Andritsos LA, et al.: Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135:642-650.
18. Hsia CC, Linenberger M, Howson-Jan K, et al.: Acute myeloid leukemia in a healthy hematopoietic stem cell donor following past exposure to a short course of G-CSF. Bone Marrow Transplant 2008; 42:431-432.
19. Makita K, Ohta K, Mugitani A, et al.: Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004; 33:661-665.
20. Tigue CC, McKoy JM, Evens AM, et al.: Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007; 40:185-192.
21. Amariglio N, Jacob-Hirsch J, Shimoni A, et al.: Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol 2007; 117:68-73.
22. Hernandez JM, Castilla C, Gutierrez NC, et al.: Mobilisation with G-CSF in healthy donors promotes a high but temporal deregulation of genes. Leukemia 2005; 19:1088-1091.
23. Hirsch B, Oseth L, Cain M, et al.: Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011; 118:2602-2608.
24. Marmier-Savet C, Larosa F, Legrand F, et al.: G-CSF-induced aneuploidy does not affect CD34+ cells and does not require cell division. Blood 2010; 115:910-911.
25. Nagler A, Korenstein-Ilan A, Amiel A, et al.: Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004; 32:122-130.
26. Sloand EM, Yong AS, Ramkissoon S, et al.: Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci USA 2006; 103:14483-14488.
27. Anderlini P, Chan FA, Champlin RE, et al.: Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 2002; 30:661-663.
28. Cavallaro AM, Lilleby K, Majolino I, et al.: Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000; 25:85-89.
29. Halter J, Kodera Y, Ispizua AU, et al.: Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009; 94:94-101.
30. Holig K, Kramer M, Kroschinsky F, et al.: Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12years of single-center experience in 3928 donors. Blood 2009; 114:3757-3763.
31. Confer DL, Shaw BE, Pamphilon DH: WMDA guidelines for subsequent donations following initial BM or PBSCs. Bone Marrow Transplant 2011; 46:1409-1412.
32. Fruehauf S, Haas R, Conradt C, et al.: Peripheral blood progenitor cell (PBPC) counts during steady-state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-metHuG-CSF)-supported cytotoxic chemotherapy. Blood 1995; 85:2619-2626.
33. Fruehauf S, Schmitt K, Veldwijk MR, et al.: Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. Br J Haematol 1999; 105:786-794.
34. Martino M, Callea I, Condemi A, et al.: Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). J Clin Apher 2006; 21:169-175.
35. Majolino I, Cavallaro AM, Bacigalupo A, et al.: Mobilization and collection of PBSC in healthy donors: a retrospective analysis of the Italian Bone Marrow Transplantation Group (GITMO). Haematologica 1997; 82:47-52.
36. Bensinger WI, Price TH, Dale DC, et al.: The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993; 81:1883-1888.
37. Brauninger S, Bialleck H, Thorausch K, et al.: Allogeneic donor peripheral blood "stem cell" apheresis: prospective comparison of two apheresis systems. Transfusion 2012; 52:1137-1145.
38. Martin-Antonio B, Carmona M, Falantes J, et al.: Impact of constitutional polymorphisms in VCAM1 and CD44 on CD34+ cell collection yield after administration of granulocyte colony-stimulating factor to healthy donors. Haematologica 2011; 96:102-109.
39. Bosi A, Bartolozzi B: Safety of bone marrow stem cell donation: a review. Transplant Proc 2010; 42:2192-2194.
40. Favre G, Beksac M, Bacigalupo A, et al.: Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003; 32:873-880.
41. Khoury H, Adkins D, Brown R, et al.: Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2000; 25:1197-1201.
42. McCullough J, Kahn J, Adamson J, et al.: Hematopoietic growth factors - use in normal blood and stem cell donors: clinical and ethical issues. Transfusion 2008; 48:2008-2025.
43. Pamphilon D, Siddiq S, Brunskill S, et al.: Stem cell donation - what advice can be given to the donor?Br J Haematol 2009; 147:71-76.
44. Stroncek DF, Clay ME, Petzoldt ML, et al.: Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996; 36:601-610.
45. McKoy JM, Stonecash RE, Cournoyer D, et al.: Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008; 48:1754-1762.
46. Schellekens H: When biotech proteins go off-patent. Trends Biotechnol 2004; 22:406-410.